Genaera — Corporate Update (August 2003)
55 slides from Genaera's corporate update, Aug 4, 2003
Slide 1: Genaera Corporation
Genaera Corporation Genaera is a biopharmaceutical company committed to developing medicines derived from genomics and natural products for serious diseases. Research and development efforts are focused on anti-angiogenesis and respiratory diseases.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management’s current views and are based on c
Slide 3: Conference Call Agenda
Conference Call Agenda Introduction Roy Levitt, MD President and Chief Executive Officer AMD Program Update Data Presentation Kenneth Holroyd, MD, MBA Executive VP and Chief Operating Officer Competitive Charles Garcia, MD Assessment Professor of Ophthalmology & Visual Science University of Texas He
Slide 4: Squalamine for AMD
Squalamine for AMD Data Presentation of Interim Results from Phase I/II Study of Squalamine for the Treatment of Choroidal Neovascularization Associated with Age-Related Macular Degeneration Kenneth J. Holroyd, MD, MBA Executive VP and Chief Operating Officer Genaera Corporation
Slide 5: Squalamine Wet AMD Trial Design
Squalamine “Wet” AMD Trial Design Phase I/II (40 patients) VA VA VA VA Baseline 1 st Week 2 nd Week 3 rd Week 4 th Week ð 2 Months ð 4 Months ñ ñ ñ ñ Squalamine Dose, Intravenous (25 or 50 mg/m 2 ) Abbreviation: VA = Visual Acuity Examination Note: Trial Design Diagram is Simplified
Slide 6: AMD Trial Endpoints and Features
AMD Trial Endpoints and Features n Most important endpoint: change in visual acuity using ETDRS (Early Treatment Diabetic Retinopathy Study) charts and scoring system n Ocular angiography and fundus photography endpoints n Safety endpoints n Internationally recognized investigators n Site in Mexico
Slide 7: Baseline Patient Demographics
Baseline Patient Demographics Number of Patients Age Range 50-92 years Mean Age 73 years Gender Male:17 Female: 23 Sub-class of AMD Classic: 45% Occult: 55%
Slide 8: Efficacy Analysis for Study Eyes
Efficacy Analysis for Study Eyes Visual Improvement at 2 Month Follow-up Evaluation Visual Acuity Line Changes 2 months (n=39) Positive Change ( ³ 3 lines) 13 (33%) Stable ( £ 2 lines) 25 (64%) Positive Change or Stable 38 (97%) Negative Change ( ³ 3 lines) 1 (3%) Range Lines Change +8 to -3 Mean Li
Slide 9: Changes by Angiographic Classification
Changes by Angiographic Classification Visual Improvement for Classic and Occult Angiographic Subtypes at 2 Months Angiographic Classification VA Line Changes Classic n=18 Occult n=21 Positive Change ( ³ 3 lines) 7 (39%) 6 (29%) Stable ( £ 2 lines) 10 (56%) 15 (71%)
Slide 10: Visual Acuity Changes by Dose
Visual Acuity Changes by Dose No Notable Difference in Visual Acuity Response in Study Eye By Dosing Group at 2 Months Dosing Group VA Line Changes 25 mg/m2 n=19 50 mg/m2 n=20 Positive Change ( ³ 3 lines) 7 (37%) 6 (30%) Stable ( £ 2 line) 11 (58%) 14 (70%)
Slide 11: Efficacy Analysis - All Affected Eyes
Efficacy Analysis - All Affected Eyes All (Including Second) Eyes Affected by Wet AMD Demonstrated Improved Vision with Squalamine Therapy Visual Acuity Line Changes 2 months (n=53) Positive Change ( > 3 lines) 15 (28%) Stable ( £ 2 lines) 36 (68%) Positive Change or Stable 51 (96%) Negative Change
Slide 12: Angiograms with Squalamine Therapy
Angiograms with Squalamine Therapy Baseline End of Treatment (4 Weeks) [PHOTO] [PHOTO] [PHOTO] [PHOTO] 2 Months 4 Months
Slide 13: Angiograms with Squalamine Therapy
Angiograms with Squalamine Therapy Baseline End of Treatment (4 Weeks) [PHOTO] [PHOTO] [PHOTO] [PHOTO] 2 Months 4 Months
Slide 14: Angiograms with Squalamine Therapy
Angiograms with Squalamine Therapy Baseline End of Treatment (4 Weeks) [PHOTO] [PHOTO] [PHOTO] [PHOTO] 2 Months 4 Months
Slide 15: Squalamine Phase I/II AMD Results Summary
Squalamine Phase I/II AMD Results Summary at 2 Months n 97% of patients had preserved or improved vision n 33% of patients had significantly improved vision n Up to 8 lines of visual acuity improvement n Good safety profile to date n Classic and occult subtypes responding n Lesions smaller in some p
Slide 16: Squalamine for AMD Competitive Assessment
Squalamine for AMD Competitive Assessment Charles A. Garcia, MD Distinguished Professor of Ophthalmology and Visual Science University of Texas Health Sciences Center, Houston Squalamine AMD Study Advisor and Participant
Slide 17: Leading Angiogenesis Inhibitors - AMD
Leading Angiogenesis Inhibitors - AMD Macugen ™ Lucentis ™ Squalamine Drug Class/Type PEGylated aptamer Humanized antibody fragment Small molecule aminosterol Location of Action Extracellular Extracellular Intracellular Mechanism of Action VEGF-165 VEGF (all isoforms) VEGF (plus other growth factors
Slide 18: Phase I and II Data Comparison
Phase I and II Data Comparison Summary Visual Acuity Line Changes at 2-3 Months Macugen ™ (n=24)* Lucentis ™ (n=53)** Squalamine (n=39) 6 positive changes ( > 3 lines) 25% 14 positive changes ( > 3 lines) 26% 13 positive changes ( > 3 lines) 33% 17 stable ( £ 2 lines) 71% 36 stable ( £ 2 lines) 69%
Slide 19: Phase I and II AMD Trial Comparisons
Phase I and II AMD Trial Comparisons Macugen ™ Lucentis ™ Squalamine Delivery for Dose Intravitreal Intravitreal Intravenous Local Eye Infection and/or Injury Yes Yes No Dosing Single or every 4 weeks x 3 Every 4 weeks x 4 Weekly x 4 Last Visual Acuity Observation Day 84-85 3 Months 4 Months Systemi
Slide 20: Macugen Trial Design Comparison
Macugen ™ Trial Design Comparison Phase II Study: 10 Patients VA VA VA Baseline 1 st Dose Day 28 Day 57 Day 85 ñ ñ ñ Macugen Dose, Intravitreal, Every 4 Weeks Phase I Study: 15 Patients VA VA VA Baseline 1 st Dose Day 28 Day 56 Day 84 ñ Macugen Dose, Intravitreal Reference #1 and Reference #2 in Sup
Slide 21: Lucentis Trial Design Comparison
Lucentis ™ Trial Design Comparison Phase I/II; 64 Patients, 4:1 radomization VA VA Baseline 1 st Dose 1 Month 2 Months 3 Months ñ ñ ñ ñ Lucentis Dose, Intravitreal or Usual Care (Observation or PDT) Reference #3 in Supplemental Information Abbreviation: VA = Visual Acuity Examination Note: Trial Des
Slide 22: Comparison of AMD Competitors
Comparison of AMD Competitors While the competition is currently more advanced in clinical development, squalamine’s potential advantages leads to the conclusion that it could become a leading drug for the treatment of wet AMD Macugen ™ Lucentis ™ Squalamine Product Company Eyetech Genentech Genaera
Slide 23: Squalamine Competitive Assessment Summary
Squalamine Competitive Assessment Summary n Intravenous squalamine delivery is less invasive, avoids complications associated with intravitreal injections n Potential for safer long-term maintenance therapy n Treat second eye with no additional risk n Improvement or preservation of vision possible n
Slide 24: Squalamine for AMD: A Perspective on Treatment Needs
Squalamine for AMD AMD: A Perspective on Treatment Needs Gerald J. Chader, PhD, MD Chief Scientific Officer The Foundation Fighting Blindness
Slide 25: AMD: Basic Types
AMD: 2 Basic Types n Dry Form : Slow atrophy of photoreceptor and PE cells, primarily in the central (macular) region of retina. It causes vision loss – occasionally severe. It accounts for about 90% of AMD cases. n Wet Form : Besides atrophy, new blood vessels grow in the macular region. Vessel gro
Slide 26: AMD Prevalence
AMD Prevalence n It is estimated that over 15 million people in the USA are affected by AMD– similar number in Europe and elsewhere. n 6 million experience some vision loss. Another 9 million are presymptomatic but show some signs (e.g., drusen) upon careful examination. n AMD is the leading cause o
Slide 27: The Medical Needs
The Needs: Medical For wet AMD, it is estimated that over 200,000 Americans (over 500,000 worldwide) are newly diagnosed each year. This presents us with the medical problem of treating a rapidly progressing, potentially blinding disease for which the current treatments are inadequate.
Slide 28: The Magnitude of the Problem in the Next Few Decades
The Magnitude of the Problem in the Next Few Decades [LOGO] The Foundation Fighting BLINDNESS New Cases of AMD Anticipated (In millions) TEN YEAR Choroidal Geographic Pre- INTERVAL Neovascularization Atrophy Symptomatic 2001-2010 2.48 2.50 21.3 2011-2020 3.14 3.20 28.2 2021-2030 3.90 4.00 35.0 Based
Slide 29: The Needs: Social Considerations
The Needs: Social Considerations n After cancer, Americans most fear blindness. n One of the main features of the world’s population has been a considerable increase in the absolute and relative numbers of older people. This phenomenon is called “population aging”. n By 2020, more than 1,000 million
Slide 30: Financial Considerations: The Costs of Blindness
Financial Considerations The Costs of Blindness n In the USA, blindness and irreversible sight impairment cost an estimated $22.3 billion in direct costs and an additional $16.1 billion in indirect costs/yr. n By 2030, not only will the population rise but the elderly population is expected to more
Slide 31: The Costs of Blindness
The Costs of Blindness These estimates of the enormous future blind population need not come about if a good wet AMD treatment is available. In our senior adult population, 65% of all severe vision loss is ascribed to AMD – mostly the wet form. Thus, any company with a strong product position in the
Slide 32: The Costs of Blindness
The Costs of Blindness The costs of blindness from wet AMD are therefore great: medically, financially and socially. Squalamine could effectively help in all these critical areas by preserving vision in seniors or even in improving it in this high-risk group. Importantly, squalamine appears to be re
Slide 33: A Summary of Squalamine Advantages
A Summary of Squalamine Advantages n Safety : non-invasive to eye, systemically safe n Efficacy : in past, treatments focused on maintaining or stabilizing vision. Now we can talk about “visual improvement” n Applicability : in past, some treatments applied to only some AMD subtypes. Now, treatment
Slide 34: Conclusion
Conclusion n Finally, there is the real possibility of safe and effective prophylactic use of squalamine when the risk of wet AMD is high. This could potentially stave off the neovascular process for the effective life of the patient; and, greatly increase the market size for the product. n Thus, Th
Slide 35: Q&A Session and Closing Remarks
Squalamine for AMD Q&A Session Closing Remarks Roy C. Levitt, MD President and Chief Executive Officer
Slide 36: Development Program Highlights
Development Program Highlights Squalamine n “Wet” AMD development n Lung cancer: Phase IIB n Prostate cancer: Phase II ($1.1 million grant) IL9 antibody n Alliance with MedImmune, Inc. n IND, clinical trial start anticipated late 2003 – milestone LOMUCIN ™ n Cystic fibrosis: Phase II results anticip
Slide 37: Squalamine for AMD Supplemental Information
Squalamine for AMD Supplemental Information Ÿ Mechanism of Action Summary and Data: Slides 38 – 45 · Additional Preclinical and Clinical Data: Slides 46 – 54 · References: Slide 55
Slide 38: Squalamine Anti-Angiogenic Product
Squalamine Anti-Angiogenic Product n Novel well characterized small molecule n Long intracellular half-life – intermittent dosing n Directly inactivates endothelial cells n Potential for broad use in eye diseases and cancers [GRAPHIC of CHEMICAL STRUCTURE] MSI-1256F
Slide 39: Squalamine Unique Multi-Faceted Mechanism
Squalamine Unique Multi-Faceted Mechanism n Enters endothelial cells selectively through membrane caveolae uptake n Calmodulin-squalamine redistribution n Inhibits action of VEGF and other growth factors n Inhibits cytoskeleton F-actin Filaments n Inhibits integrin expression a v ß 3 [PHOTO] Control
Slide 40: Squalamine Mechanism Of Action
Squalamine Mechanism Of Action Growth factors (vEGF, bFGF, etc.) Capillary formation (angiogenesis) [GRAPHIC] [GRAPHIC] Endothelial Cell Squalamine chaperones calmodulin Decreased motility & integrin expression Squalamine [GRAPHIC] [GRAPHIC] Growth factor signals aborted Endothelial cell apoptosis
Slide 41: Squalamine Inhibits VEGF Signaling
Squalamine Inhibits VEGF Signaling VEGF-Stimulated Tyrosine Phosphorylation of MAP Kinase in HUVEC VEGF SQ VEGF+SQ Cn 10’ 30’ Cn 10” 30” [PICTURE] – phospho –p44 MAPK – phospho –p42 MAPK *Reference #4 in Supplemental Information
Slide 42: Squalamine on F-actin & Adhesion
Squalamine on F-actin & Adhesion Inhibition of Actin Stress Fiber Formation and Focal Adhesion F-actin Filaments [PHOTO] [PHOTO] (visualized by staining with phalloidin) Focal Adhesion Sites [PHOTO] [PHOTO] (visualized with anti-vinculin antibody) Control + Squalamine
Slide 43: Squalamine Entry into HUVECs
Squalamine Entry into HUVECs Caveolae Disruption with Filipin Blocks Uptake of Red Fluorescence-Labeled Squalamine [PHOTO] [PHOTO] HUVECs, Controls HUVECs Treated with Filipin (5 µg/mL)
Slide 44: Calmodulin-Squalamine Redistribution
Calmodulin-Squalamine Redistribution After Entry into Activated Endothelial Cells, Squalamine and Calmodulin Bind, and the Complex is Transported to a Peri-Nuclear Membrane Compartment [PHOTO] [PHOTO] Control Squalamine-Treated FITC (green fluorescence) labeled anti-calmodulin antibody
Slide 45: Calmodulin Capture by Squalamine
Calmodulin Capture by Squalamine Squalamine Affinity Column 1 = IEF Standards (pH 3-7) [PHOTO] 2 = Proteins Bound by Squalamine Affinity Gel Calmodulin ð 3 = Proteins Bound by MSI-1409 Affinity Gel 1 2 3
Slide 46: Squalamine Efficacy in Primate Ocular Model
Squalamine Efficacy in Primate Ocular Model Iris photograph of a control animal after 2 weeks of CRVO shows many new vessels on the iris surface as well as hyphema [PHOTO] [PHOTO] Corneal but no iris neovascularization is evident after 3 weeks (twice weekly systemic dosing at 12 mg/m2) of squalamine
Slide 47: Baseline Characteristics Supplement
Baseline Characteristics Supplement AMD angiographic sub-classification Completely classic % Predominantly classic % Predominantly occult % Completely occult %
Slide 48: Efficacy Analysis in Study Eyes
Efficacy Analysis in Study Eyes Visual acuity changes End of Treatment 2 month follow-up 3 or more lines gain 33% 33% 2 or more lines gain 48% 44% 1 or more lines gain 70% 59% 0 or more lines gain 93% 79%
Slide 49: Baseline Median Visual Acuity
Baseline Median Visual Acuity Wet AMD Study Eyes All (Including Second) Wet AMD Eyes Second Eyes Thought Unaffected by Wet AMD
Slide 50: Efficacy Analysis for Study Eyes
Efficacy Analysis for Study Eyes Visual Improvement at EOT and Follow-up Evaluations Visual Acuity Line Changes EOT (n=40) 2 months (n=39) Positive Change ( ³ 3 lines) 13 (33%) 13 (33%) Stable ( £ 2 lines) 27 (67%) 25 (64%) Positive Change or Stable 40 (100%) 38 (97%) Negative Change ( ³ 3 lines) 0
Slide 51: Changes by Angiographic Classification
Changes by Angiographic Classification Visual Improvement for Classic and Occult Angiographic Subtypes at End of Therapy and 2 Months VA Line Changes Angiographic Classification EOT; n=40 18 Classic 22 Occult 2 months; n=39 18 classic 21 occult Positive Change ( ³ 3 lines) Classic 5 (28%) 7 (39%) Oc
Slide 52: Visual Acuity Changes by Dose
Visual Acuity Changes by Dose No Notable Difference in Study Eyes Response By Dose at End of Therapy and 2 Months VA Line Changes Dose (mg/m 2 ) EOT; n=40 20 at 25 mg/m 2 20 at 50 mg/m 2 2 months; n=39 19 at 25 mg/m 2 20 at 50 mg/m 2 Positive Change ( ³ 3 lines) 7 (35%) 6 (30%) 7 (37%) 6 (30%) Stabl
Slide 53: Efficacy Analysis for All Affected Eyes
Efficacy Analysis for All Affected Eyes All (Including Second) Eyes Affected by Wet AMD Demonstrated Improved Vision with Squalamine Therapy Visual Acuity Line Changes EOT (n=54) 2 months (n=53) Positive Change ( ³ 3 lines) 17 (31%) 15 (28%) Stable ( £ 2 lines) 36 (67%) 36 (68%) Positive Change or S
Slide 54: Efficacy Analysis for Non-Affected Eyes
Efficacy Analysis for Non-Affected Eyes Second Eyes Thought to be Unaffected by Wet AMD have a Minimal Response: A Useful Internal Control for Study Visual Acuity Line Changes EOT (n=25) 2 months (n=24) Positive Change ( ³ 3 lines) 3 (12%) 3 (12%) Stable ( £ 2 lines) 20 (80%) 20 (83%) Positive Chang
Slide 55: References
References 1. Preclinical and Phase 1A Clinical Evaluation of an Anti-VEGF PEGylated Aptamer (EYE001) for the Treatment of Exudative Age-Related Macular Degeneration. The Eyetech Study Group. Retina. 2002;22(2). 2. Anti-vascular Endothelial Growth Factor Therapy for Subfoveal Choroidal Neovasculariz